Large company small molecule share of Phase I clinical trial starts
Global, 2022 to 2025
66%
2025
Large company small molecule share of Phase I clinical trial starts: Global, 2022 to 2025
Large company small molecule share of Phase I clinical trial starts: Global, 2022 to 2025. 2 observations from 2022 to 2025, ranging from 61% to 66%. Latest value 66% (2025).
%
0
20
40
60
80
2022
2023
2024
2025
61%
66%
Large company small molecule share of Phase I clinical trial starts: Global, 2022 to 2025
Large company small molecule share of Phase I clinical trial starts: Global, 2022 to 2025. 2 observations from 2022 to 2025, ranging from 61% to 66%. Latest value 66% (2025).
%
0
20
40
60
80
2022
2023
2024
2025
61%
66%
Large company small molecule share of Phase I clinical trial starts: Global, 2022 to 2025
Large company small molecule share of Phase I clinical trial starts: Global, 2022 to 2025. 2 observations from 2022 to 2025, ranging from 61% to 66%. Latest value 66% (2025).
%
0
20
40
60
80
2022
2023
2024
2025
61%
66%
View the underlying data
Large company small molecule share of Phase I clinical trial starts: Global, 2022 to 2025
Period
Type
Value
2022
Actual
61%
2025
Actual
66%
Chart:
StatOrigin
· Source: IQVIA ·
statorigin.org
CC BY 4.0